Yes, Ebglyss Treats Moderate-to-Severe Atopic Dermatitis
Ebglyss (lebrikizumab-lbkz) is an FDA-approved biologic injection for adults with moderate-to-severe atopic dermatitis, the medical term for eczema. It targets interleukin-13 (IL-13), a protein driving skin inflammation, itch, and barrier dysfunction in eczema.[1] Eli Lilly received approval in September 2024 after phase 3 trials showed significant clearance of skin lesions and reduced itching compared to placebo.[2]
How Ebglyss Fits into Eczema Treatment Options
Ebglyss is given as a 250 mg subcutaneous injection every two weeks after initial loading doses, then maintenance every four weeks for responders. It's for patients whose eczema doesn't respond well to topical therapies. Dupixent (dupilumab), an IL-4/IL-13 blocker, was the first biologic for this use and remains the market leader, but Ebglyss offers an alternative with potentially fewer injections long-term.[1][3]
| Treatment | Target | Dosing Frequency (Maintenance) | Approval Year |
|-----------|--------|-------------------------------|---------------|
| Ebglyss | IL-13 | Every 4 weeks | 2024 |
| Dupixent | IL-4/IL-13 | Every 2-4 weeks | 2017 |
| Adbry | IL-13 | Every 2 weeks | 2020 |
Who Qualifies and What Do Trials Show
Eligible patients are 12+ (pending pediatric approval) with eczema covering at least 10% body surface area, failing topicals. ADvocate1 and ADvocate2 trials (n=716) hit primary endpoints: 43% achieved clear/almost clear skin (IGA 0/1) vs. 13% placebo at week 16, with 33% itch-free nights vs. 11%.[2] Long-term data through week 52 sustained these results.
Common Side Effects and Patient Concerns
Most issues are mild: eye inflammation (conjunctivitis, 7-11%), herpes infections (3-5%), injection site reactions (2-3%). No black-box warnings, but monitor for hypersensitivity. Patients report less injection burden than weekly options.[1][2]
Pricing, Access, and Insurance Coverage
List price is about $7,000/month, similar to competitors, but copay cards cap out-of-pocket at $0-25 for eligible insured patients via Lilly's program. Medicare Part D covers it; prior authorizations focus on trial of topicals.[4]
Patent Status and Future Competition
Ebglyss is under Lilly's lebrikizumab patents, with key U.S. composition-of-matter expiry around 2032-2034 (check DrugPatentWatch.com for updates).[5] No biosimilars yet, but challenges could accelerate generics post-exclusivity.
[1]: FDA Label - Ebglyss (https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761350s000lbl.pdf)
[2]: NEJM - Lebrikizumab Phase 3 Trials (https://www.nejm.org/doi/full/10.1056/NEJMoa2308673)
[3]: Dermatology Times - Ebglyss Approval (https://www.dermatologytimes.com/view/fda-approves-lilly-s-ebglyss-for-atopic-dermatitis)
[4]: Lilly Patient Assistance (https://www.ebglyss.com/savings)
[5]: DrugPatentWatch.com - Lebrikizumab Patents (https://www.drugpatentwatch.com/p/tradename/EBGLYSS)